PROYECTO DE BIOMEDICINA CIMA, S.L. Patent applications |
Patent application number | Title | Published |
20160074475 | CONJUGATES FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE COMPOUNDS - The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the Apo A molecule. | 03-17-2016 |
20140056943 | IMMUNO-STIMULANT COMBINATION FOR PROPHYLAXIS AND TREATMENT OF HEPATITIS C - The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus. | 02-27-2014 |
20130130225 | COMPOSITION FOR THE COLD STORAGE OF ORGANS - The present invention relates to a cold organ preservation composition for transplantation comprising a cold organ preservation solution and cardiotrophin-1 or a functionally equivalent variant thereof. The invention also relates to methods and kits for the preparation of said composition, the uses thereof for the cold organ protection and/or preservation for transplantation (particularly for kidney, lung and heart) and also to the cold preservation methods and cold-preserved isolated organs by these methods. | 05-23-2013 |
20130064790 | PEPTIDES WITH THE CAPACITY TO BIND TO INTERLEUKIN-10 (IL-10) - The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions. | 03-14-2013 |
20120315256 | USE OF TRANSFORMING GROWTH FACTOR - BETA 1 (TGF-B1) INHIBITOR PEPTIDES FOR THE TREATMENT OF CORNEAL FIBROSIS AND/OR HAZE - The invention refers to the use of transforming growth factor-beta 1 (TGF-β1) inhibitor peptides or polynucleotides encoding said peptides for the prevention and/or treatment of corneal fibrosis and/or corneal haze. | 12-13-2012 |
20120308517 | COMPOSITIONS FOR THE TREATMENT OF INFECTIOUS AND TUMOURAL DISEASES - The present invention relates to the use of compositions comprising a type III interferon and oncostatin M and to the use of said compositions for the treatment and prevention of infectious and neoplastic diseases. | 12-06-2012 |
20120237535 | Therapeutic Compositions For The Treatment of HPV-Induced Diseases - The invention relates to immunogenic conjugates comprising an immunogenic region of human papilloma virus E7 protein and the fibronectin EDA region, as well to compositions comprising said conjugates and to dendritic cells obtained by stimulation with said conjugates and compositions. Moreover, the invention relates to methods for the treatment of diseases caused by the human papilloma virus (HPV) using said conjugates, compositions and dendritic cells. | 09-20-2012 |
20120093775 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CIRRHOSIS AND LIVER FIBROSIS - The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding IGF-I. The invention discloses both parvoviral vectors and SV40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation of said viral vectors. | 04-19-2012 |
20120083464 | NEUROPROTECTIVE PROPERTIES OF 5'-METHYLTHIOADENOSINE - The present invention relates to the use of MTA, its pharmaceutically acceptable salts and/or prodrugs thereof as active ingredient in the manufacture of a medicament for the prevention or treatment of nerve cell death or damage, a neuroprotective medicament, a medicament for the regeneration of nerve cells, and a medicament for the prevention or treatment of a neurological or psychiatric disease. The present invention also relates to a method of prevention or treatment of nerve cell death or damage, a method of neuroprotection, a method of regenerating nerve cells and a method of prevention or treatment of a neurological or psychiatric disease. | 04-05-2012 |
20110293562 | USE OF CARDIOTROPHIN-1 FOR THE TREATMENT OF METABOLIC DISEASES - The invention is related to the use of cardiotrophin-1 (CT-1) for the treatment of obesity and associated disorders: hyperglycaemias, insulin resistance, development of type 2 diabetes and dyslipemias and given its anorexigenic role, fat oxidation stimulant, hypoglycaemic, sensitizing agent of the action of insulin on a skeletal muscle level and inhibitor of the intestinal transport of glucose by enterocytes. | 12-01-2011 |
20110293557 | CONJUGATES FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE COMPOUNDS - The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the ApoA molecule. | 12-01-2011 |
20110268757 | USE OF PHENOL-SOLUBLE MODULINS FOR VACCINE DEVELOPMENT - The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSMα, PSMγ and PSMδ peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo. Thus, the PSMα, PSMγ and PSMδ peptides bound to these antigens may be used in the development of vaccines for preventing or treating infectious diseases or cancer | 11-03-2011 |
20110262399 | PORPHOBILINOGEN DEAMINASE GENE THERAPY - The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3. | 10-27-2011 |
20110195047 | ONCOSTATIN M AS PROMOTER OF IMMUNOSTIMULATORY ACTIVITY OF HUMAN EPITHELIAL CELLS - The invention relates to the use of oncostatin M (OSM), an OSM receptor (OSMR) agonist, or a combination of OSM or a OSMR agonist with an interferon type I; in the manufacture of a medicament for enhancing the immunostimulatory activity of epithelial cells in a human. | 08-11-2011 |
20110081718 | SYSTEM FOR PACKAGING HIGH-CAPACITY ADENOVIRUSES - The invention relates to a nuew system for production and packaging of high capacity adenoviral vectors which does not require the use of helper virues and which is characterized in that it integrates the adenoviral genes needed for the control, replication and packaging of the viral particuiles in the genome of a host cell, which results in the improvement of the long term stability of the production system. | 04-07-2011 |
20110076304 | ADAPTER MOLECULE FOR THE DELIVERY OF ADENOVIRUS VECTORS - The invention relates to an adapter protein comprising a coxackievirus and adenovirus receptor (CAR) region and a human CD40 ligand and to the uses thereof for promoting adenoviral transduction of dendritic cells while at the same time promoting maturation of the DCs. The invention also relates to pharmaceutical compositions comprising said adapter protein and an adenovirus encoding an antigen and the uses thereof in a method for eliciting an immune response against the antigen encoded in said adenovirus as well as to antigen-loaded dendritic cells obtained the adaptor protein and an adenovirus and to the uses thereof in a method of eliciting an immune response against the antigen encoded in the adenovirus. | 03-31-2011 |
20110070623 | SELF-INACTIVATING HELPER ADENOVIRUSES FOR THE PRODUCTION OF HIGH-CAPACTIY RECOMBINANT ADENOVIRUSES - The invention relates to reagents and methods for the generation of auto-inactivating helper adenoviruses that allow the development of cell systems for the generation of high-capacity recombinant adenovirus showing a reduced contamination by auxiliary adenoviruses. | 03-24-2011 |
20110030075 | Methods and Compositions Capable of Causing Post-Transcriptional Silencing of Gene Expression in a Synergic Manner - The invention relates to compositions for the post-transcriptional inhibition of gene expression by means of the combined use of a modified U1 snRNA targeted at a pre-selected region in a target pre-mRNA and of a gene expression-silencing agent of the siRNA, shRNA and/or miRNA type, as well as the use of said combinations for the treatment of diseases caused by the unwanted over-expression of a protein. | 02-03-2011 |
20110015132 | SYNERGISTIC 5'-METHYLTHIOADENOSINE COMBINATIONS - The present invention relates to combinations of 5′-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5′-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis. | 01-20-2011 |
20100267623 | PEPTIDES WITH CAPACITY TO BIND TO SCURFIN AND APPLICATIONS - The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X | 10-21-2010 |
20100168015 | PEPTIDES WITH CAPACITY FOR BINDING WITH INTERLEUKINE 10 (IL-10) - The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions. | 07-01-2010 |
20100055736 | VIRAL VECTOR AND USES THEREOF - The invention relates to a viral vector comprising a mutated replicon of the Semliki Forest virus (SFV) in the nucleotide sequence encoding subunit nsp2 of the SFV replicase. Said viral vector can be used to generate stable cell lines which can constitutively express heterologous products of interest. | 03-04-2010 |
20090312332 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION - Adenosine A | 12-17-2009 |
20090263410 | USE OF TGF-B1 INHIBITOR PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT - The present invention relates to the use of a peptide inhibiting TGF-β1 selected from: peptide p144 whose sequence corresponds to SEQ ID NO: 1, peptide p17 whose sequence corresponds to SEQ ID NO: 2, a peptide which has at least 90% homology therewith, or fragments of the above, in the preparation of an immune response modulating agent. | 10-22-2009 |
20090117591 | Fibrosis Markers - The invention relates to the use of a combination of at least two markers that are selected from among Uromodulin, MAC2BP, AGP1 and Cathepsin A, for the in vitro detection of fibrotic alterations. In addition, the invention relates to a kit for determining the levels of said markers in a biological sample. | 05-07-2009 |
20090042831 | USE OF 5'-METHYLTHIOADENOSINE (MTA) IN THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR TRANSPLANT REJECTION - 5′-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (MS), as well as in the prevention and/or treatment of transplant rejection. | 02-12-2009 |